[{"id":"7e4f81a6-72f5-4f86-a545-a5378d007797","acronym":"","url":"https://clinicaltrials.gov/study/NCT05463601","created_at":"2022-07-19T15:55:10.839Z","updated_at":"2024-07-02T16:35:50.729Z","phase":"Phase 2","brief_title":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer","source_id_and_acronym":"NCT05463601","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • letrozole • exemestane • AiRuiKang (dalpiciclib) • HHPG-19K (mecapegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-12"},{"id":"4d4aa8d5-9575-498a-a4a0-d10dc78114a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05294055","created_at":"2022-03-24T13:52:36.811Z","updated_at":"2024-07-02T16:35:59.720Z","phase":"Phase 2","brief_title":"Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma","source_id_and_acronym":"NCT05294055","lead_sponsor":"Qiu Lugui","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • HHPG-19K (mecapegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/26/2022","start_date":" 04/26/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2022-12-02"}]